Liraglutide: difference between revisions
Diff·revision 12 → 13·20:05, 4 Jan 2025
Difference between revision 12 and revision 13 of Liraglutide. 6 lines changed; the page grew by 124 bytes.
| Revision 12 — 15:04, 18 Dec 2024 MazdutideMads (talk) fix hyphenation per PP:MOS 4,171 bytes +898 | Revision 13 — 20:05, 4 Jan 2025 ArchiveBot (talk) bot: sort category members 4,295 bytes +124 | ||
|---|---|---|---|
| 41 | <ref name="marso2016">Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." ''New England Journal of Medicine'' 375(4):311–322 (2016). DOI:10.1056/NEJMoa1603827. PMID 27295427.</ref> | 41 | <ref name="marso2016">Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." ''New England Journal of Medicine'' 375(4):311–322 (2016). DOI:10.1056/NEJMoa1603827. PMID 27295427.</ref> |
| 42 | 42 | ||
| + | 43 | == See also == | |
| + | 44 | * [[GLP-1 receptor agonist]] | |
| + | 45 | * [[Semaglutide]] | |
| + | 46 | * [[Albumin binding half-life extension]] | |
| + | 47 | * [[LEADER trial]] | |
| + | 48 | ||
| 43 | {{DEFAULTSORT:Liraglutide}} | 49 | {{DEFAULTSORT:Liraglutide}} |
| 44 | [[Category:GLP-1 receptor agonists]] | 50 | [[Category:GLP-1 receptor agonists]] |